PIK3CD and cancer: Inhibitors of PI3Kγ and δ like duvelisib (Verastem, Needham, MA, USA) and idelalisib (Gilead, Foster City, CA, USA) are limited to administration in patients with cancers of the immune system since these two PI3K isoforms are expressed in immune cells only [27,28].